You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Vinorelbine

Showing 1 - 25 of 598
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer Trial in Xi'an (metronomic oral vinorelbine plus anlotinib)

Recruiting
  • Breast Cancer
  • metronomic oral vinorelbine plus anlotinib
  • Xi'an, Shaanxi, China
    Xi'an International Medical Center Hospital
Aug 27, 2023

Inetetamab Combined With Pyrotinib and Vinorelbine in ABC

Recruiting
  • HER2-positive Advanced Breast Cancer
  • Inetetamab Combined With Pyrotinib and Vinorelbine
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
May 3, 2023

EGFR, NSCLC, Third-generation TKI Trial (Almonertinib and metronomic oral vinorelbine)

Not yet recruiting
  • EGFR
  • +2 more
  • Almonertinib and metronomic oral vinorelbine
  • (no location specified)
Dec 21, 2022

Breast Cancer Trial in Nanjing (Inetetamab, Pyrotinib, Oral Vinorelbine Tartrate)

Recruiting
  • Breast Cancer
  • Nanjing, Jiangsu, China
    The First Affiliated Hospital with Nanjing Medical University
Apr 10, 2023

Breast Cancer Trial in Beijing (oral vinorelbine and capecitabine)

Recruiting
  • Breast Cancer
  • oral vinorelbine and capecitabine
  • Beijing, Beijing, China
    National Cancer Center/National Clinical Research Center for Can
Feb 27, 2023

Breast Cancer Trial in Zhengzhou (anlotinib and vinorelbine, Vinorelbine injection)

Recruiting
  • Breast Cancer
  • anlotinib and vinorelbine
  • Vinorelbine injection
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Aug 2, 2022

Inetetamab Combined With Pyrotinib and Vinorelbine as First-line

Recruiting
  • Breast Neoplasms
  • Nanjing, Jiangsu, China
    Jiangsu Provincial People's Hospital
Mar 16, 2023

HER2-positive Breast Cancer Trial in Nanjing (HS022, Trastuzumab, Vinorelbine Bitartrate)

Completed
  • HER2-positive Breast Cancer
  • Nanjing, Jiangsu, China
    Jiangsu Province People's Hospital (First Affiliated Hospital of
Oct 25, 2023

Anaplastic Large Cell Lymphoma, Vinorelbine Trial in Shanghai (Vinorelbine)

Completed
  • Anaplastic Large Cell Lymphoma
  • Vinorelbine
  • Vinorelbine
  • Shanghai, Shanghai, China
    Shanghai Children's Medical Center
Jul 23, 2022

Non Small Cell Lung Cancer (NSCLC), Malignant Pleural Mesothelioma (MPM) Trial in Marseille (Vinorelbine)

Completed
  • Non Small Cell Lung Cancer (NSCLC)
  • Malignant Pleural Mesothelioma (MPM)
  • Vinorelbine
  • Marseille, France
    Assistance Publique des Hôpitaux de Marseille (CEPCM)
Nov 15, 2022

Breast Cancer, Pyrotinib, Breast Diseases Trial in Guangzhou (Pyrotinib 320mg + Vinorelbine, Pyrotinib 400mg + Vinorelbine,

Recruiting
  • Breast Cancer
  • +4 more
  • Pyrotinib 320mg + Vinorelbine
  • +2 more
  • Guangzhou, China
    Zhang Jingmin
Apr 24, 2022

HER2-negative Breast Cancer, Neoadjuvant Therapy, Pathological Complete Response Trial in Beijing (Camrelizumab with vinorelbine

Recruiting
  • HER2-negative Breast Cancer
  • +5 more
  • Camrelizumab with vinorelbine and cisplatin
  • Beijing, Beijing, China
    Peking University First Hospital
Oct 15, 2022

Advanced NSCLC Trial in Guangzhou (Surufatinib, Surufatinib Plus Vinorelbine)

Recruiting
  • Advanced Non-Small Cell Lung Cancer
  • Guangzhou, Guangdong, China
    Affiliated Cancer Hospital and Institute of Guangzhou Medical Un
Aug 18, 2022

Rhabdomyosarcoma Trial in Los Angeles (Vinorelbine, Mocetinostat)

Recruiting
  • Rhabdomyosarcoma
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
May 13, 2022

NSCLC, Carcinoma Breast Trial in Suzhou (Vinorelbine, Radiotherapy, PD-1/PD-L1 inhibitor)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma Breast
  • Vinorelbine
  • +4 more
  • Suzhou, China
    Second Affiliated Hospital of Soochow University
Oct 29, 2022

Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine

Completed
  • Breast Cancer
    • Shanghai, China
      Fudan University Shanghai Cancer Center
    Jun 30, 2022

    Breast Carcinoma, Metastatic Malignant Tumor in the Brain, Metastatic Malignant Tumor in the Leptomeninges Trial in Chicago

    Not yet recruiting
    • Breast Carcinoma
    • +2 more
    • Biospecimen Collection
    • +6 more
    • Chicago, Illinois
      Northwestern University
    Nov 14, 2023

    Hodgkin Lymphoma Trial in Moscow (Nivolumab)

    Recruiting
    • Hodgkin Lymphoma
    • Moscow, Russian Federation
      National Research Center for Hematology
    Dec 13, 2022

    HER2-positive Advanced Breast Cancer Trial (DP303c, Trastuzumab, Vinorelbine Tartrate)

    Not yet recruiting
    • HER2-positive Advanced Breast Cancer
    • (no location specified)
    Jun 4, 2023

    HER2-positive Advanced Breast Cancer Trial in Tianjin (Pyrotinib Maleate, Vinorelbine)

    Completed
    • HER2-positive Advanced Breast Cancer
    • Pyrotinib Maleate
    • Vinorelbine
    • Tianjin, China
      Tianjin Cancer Hospital
    Apr 6, 2022

    Metastatic Breast Cancer Trial in Beijing (Vinorelbine 40mg, Toripalimab 240mg, Bevacizumab 5 mg/kg)

    Recruiting
    • Metastatic Breast Cancer
    • Vinorelbine 40mg
    • +5 more
    • Beijing, Beijing, China
    • +1 more
    Feb 9, 2022

    Advanced Solid Tumours, Breast Cancer, Head Neck Cancer Trial in France (Durvalumab + Tremelimumab + metronomic Vinorelbine)

    Active, not recruiting
    • Advanced Solid Tumours
    • +4 more
    • Durvalumab + Tremelimumab + metronomic Vinorelbine
    • Angers, France
    • +8 more
    Jun 1, 2022

    Mesothelioma Trial in Cardiff (Vinorelbine, Active Symptom Control)

    Completed
    • Mesothelioma
    • Vinorelbine
    • Active Symptom Control
    • Cardiff, United Kingdom
      Wales Cancer Trials Unit
    Oct 4, 2021

    Metastatic Breast Cancer Trial in Hangzhou (Cipterbin Combined With Vinorelbine)

    Recruiting
    • Metastatic Breast Cancer
    • Cipterbin Combined With Vinorelbine
    • Hangzhou, Zhejiang, China
      Zhejiang Cancer Hospital
    Nov 11, 2021

    Non Hodgkin Lymphoma Trial (Liposomal Mitoxantrone Hydrochloride dose level 1, Liposomal Mitoxantrone Hydrochloride dose level

    Not yet recruiting
    • Non Hodgkin Lymphoma
    • Liposomal Mitoxantrone Hydrochloride dose level 1
    • +6 more
    • (no location specified)
    Mar 17, 2022